HOPO Therapeutics just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on HOPO Therapeutics, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
HOPO Therapeutics Awarded $226 Million Contract from BARDA for Advanced Development of Oral Decorporation Agent
Contract Type
contract
BerkeleyManufacturingBiotechnologyDescription
HOPO Therapeutics, Inc. has been awarded a contract valued at up to $226 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance the development of the drug candidate HOPO-101 as a medical countermeasure against radiological threats. The funds will be used for toxicology and pharmacology studies, manufacturing activities, and nonclinical research in heavy metal poisoning, with additional funding available for later-stage development upon agreement between BARDA and HOPO.